Infective endocarditis: Difference between revisions
From IDWiki
(→: missed one) |
(→: changed the formatting) |
||
Line 42: | Line 42: | ||
|- |
|- |
||
| rowspan=3 | PVE |
| rowspan=3 | PVE |
||
− | | [[oxacillin]] |
+ | | [[oxacillin]] |
| 2 g IV q4h |
| 2 g IV q4h |
||
| rowspan=2 | ≥6 weeks |
| rowspan=2 | ≥6 weeks |
||
| rowspan=3 | use cefazolin or vancomycin if allergy |
| rowspan=3 | use cefazolin or vancomycin if allergy |
||
|- |
|- |
||
− | | [[rifampin]] |
+ | | + [[rifampin]] |
| 300 mg IV/PO q8h |
| 300 mg IV/PO q8h |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 1 mg/kg IV/IM q8h |
| 1 mg/kg IV/IM q8h |
||
| 2 weeks |
| 2 weeks |
||
Line 65: | Line 65: | ||
|- |
|- |
||
| rowspan=3 | PVE |
| rowspan=3 | PVE |
||
− | | [[vancomycin]] |
+ | | [[vancomycin]] |
| 15 mg/kg IV q12h |
| 15 mg/kg IV q12h |
||
| rowspan=2 | ≥6 weeks |
| rowspan=2 | ≥6 weeks |
||
| rowspan=3 | target vancomycin trough of 10-20 μg/mL |
| rowspan=3 | target vancomycin trough of 10-20 μg/mL |
||
|- |
|- |
||
− | | [[rifampin]] |
+ | | + [[rifampin]] |
| 300 mg IV/PO q8h |
| 300 mg IV/PO q8h |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 1 mg/kg IV/IM q8h |
| 1 mg/kg IV/IM q8h |
||
| 2 weeks |
| 2 weeks |
||
Line 80: | Line 80: | ||
|- |
|- |
||
| rowspan=2 | NVE or PVE |
| rowspan=2 | NVE or PVE |
||
− | | [[ampicillin]] |
+ | | [[ampicillin]] |
| 2 g IV q4h |
| 2 g IV q4h |
||
| rowspan=2 | 4-6 weeks |
| rowspan=2 | 4-6 weeks |
||
| rowspan=2 | 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or if PVE |
| rowspan=2 | 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or if PVE |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 1 mg/kg IV q8h |
| 1 mg/kg IV q8h |
||
|- |
|- |
||
| rowspan=2 | NVE or PVE |
| rowspan=2 | NVE or PVE |
||
− | | [[ampicillin]] |
+ | | [[ampicillin]] |
| 2 g IV q4h |
| 2 g IV q4h |
||
| rowspan=2 | 6 weeks |
| rowspan=2 | 6 weeks |
||
| rowspan=2 | alternative regimen if CrCl <50 |
| rowspan=2 | alternative regimen if CrCl <50 |
||
|- |
|- |
||
− | | [[ceftriaxone]] |
+ | | + [[ceftriaxone]] |
| 2 g IV q12h |
| 2 g IV q12h |
||
|- |
|- |
||
Line 100: | Line 100: | ||
|- |
|- |
||
| rowspan=2 | NVE or PVE |
| rowspan=2 | NVE or PVE |
||
− | | [[ampicillin]] |
+ | | [[ampicillin]] |
| 2 g IV q4h |
| 2 g IV q4h |
||
| rowspan=2 | 6 weeks |
| rowspan=2 | 6 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[ceftriaxone]] |
+ | | + [[ceftriaxone]] |
| 2 g IV q12h |
| 2 g IV q12h |
||
|- |
|- |
||
Line 111: | Line 111: | ||
|- |
|- |
||
| rowspan=2 | NVE or PVE |
| rowspan=2 | NVE or PVE |
||
− | | [[vancomycin]] |
+ | | [[vancomycin]] |
| 15 mg/kg IV q12h |
| 15 mg/kg IV q12h |
||
| rowspan=2 | 6 weeks |
| rowspan=2 | 6 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 1 mg/kg IV/IM q8h |
| 1 mg/kg IV/IM q8h |
||
|- |
|- |
||
Line 148: | Line 148: | ||
|- |
|- |
||
| rowspan=2 | NVE |
| rowspan=2 | NVE |
||
− | | [[penicillin]] or [[ceftriaxone]] |
+ | | [[penicillin]] or [[ceftriaxone]] |
| as above |
| as above |
||
| rowspan=2 | 2 weeks |
| rowspan=2 | 2 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 3 mg/kg IV/IM q24h |
| 3 mg/kg IV/IM q24h |
||
|- |
|- |
||
Line 162: | Line 162: | ||
| use if allergy, target 10-15 μg/mL |
| use if allergy, target 10-15 μg/mL |
||
|- |
|- |
||
− | | rowspan= |
+ | | rowspan=2 | PVE |
− | | crystalline [[penicillin]] G |
+ | | crystalline [[penicillin]] G |
| 6 MU IV q4h |
| 6 MU IV q4h |
||
− | + | | 6 weeks |
|
− | | rowspan= |
+ | | rowspan=2 | |
|- |
|- |
||
+ | | ± [[gentamicin]] |
||
⚫ | |||
+ | | 3 mg/kg IV/IM q24h |
||
+ | | 2 weeks |
||
+ | |- |
||
+ | | rowspan=2 | PVE |
||
⚫ | |||
| 2 g IV/IM q24h |
| 2 g IV/IM q24h |
||
+ | | 6 weeks |
||
+ | | rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | ± [[gentamicin]] |
| 3 mg/kg IV/IM q24h |
| 3 mg/kg IV/IM q24h |
||
| 2 weeks |
| 2 weeks |
||
Line 184: | Line 191: | ||
|- |
|- |
||
| rowspan=2 | NVE |
| rowspan=2 | NVE |
||
− | | crystalline [[penicillin]] G |
+ | | crystalline [[penicillin]] G |
| 6 MU IV q4h |
| 6 MU IV q4h |
||
| 4 weeks |
| 4 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 3 mg/kg IV/IM q24h |
| 3 mg/kg IV/IM q24h |
||
|- |
|- |
||
Line 198: | Line 205: | ||
| use if allergy, target 10-15 μ/mL |
| use if allergy, target 10-15 μ/mL |
||
|- |
|- |
||
− | | rowspan= |
+ | | rowspan=2 | PVE |
− | | crystalline [[penicillin]] G |
+ | | crystalline [[penicillin]] G |
| 6 MU IV q4h |
| 6 MU IV q4h |
||
− | | rowspan= |
+ | | rowspan=2 | 6 weeks |
− | | rowspan= |
+ | | rowspan=2 | |
|- |
|- |
||
− | | [[ |
+ | | + [[gentamicin]] |
+ | | 3 mg/kg IV/IM q24h |
||
+ | |- |
||
+ | | rowspan=2 | PVE |
||
+ | | [[ceftriaxone]] |
||
| 2 g IV/IM q24h |
| 2 g IV/IM q24h |
||
+ | | rowspan=2 | 6 weeks |
||
+ | | rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | + [[gentamicin]] |
| 3 mg/kg IV/IM q24h |
| 3 mg/kg IV/IM q24h |
||
|- |
|- |
||
Line 243: | Line 256: | ||
|- |
|- |
||
| rowspan=2 | NVE |
| rowspan=2 | NVE |
||
− | | crystalline [[penicillin]] G |
+ | | crystalline [[penicillin]] G |
| |
| |
||
| 4 weeks |
| 4 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | ± [[gentamicin]] |
| |
| |
||
| 2 weeks |
| 2 weeks |
||
|- |
|- |
||
| rowspan=2 | NVE |
| rowspan=2 | NVE |
||
− | | [[ceftriaxone]] |
+ | | [[ceftriaxone]] |
| |
| |
||
| 4 weeks |
| 4 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | ± [[gentamicin]] |
| |
| |
||
| 2 weeks |
| 2 weeks |
||
|- |
|- |
||
| rowspan=2 | PVE |
| rowspan=2 | PVE |
||
− | | crystalline [[penicillin]] G |
+ | | crystalline [[penicillin]] G |
| |
| |
||
| 6 weeks |
| 6 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | ± [[gentamicin]] |
| |
| |
||
| 2 weeks |
| 2 weeks |
||
|- |
|- |
||
| rowspan=2 | PVE |
| rowspan=2 | PVE |
||
− | | [[ceftriaxone]] |
+ | | [[ceftriaxone]] |
| |
| |
||
| 6 weeks |
| 6 weeks |
||
| rowspan=2 | |
| rowspan=2 | |
||
|- |
|- |
||
− | | [[gentamicin]] |
+ | | ± [[gentamicin]] |
| |
| |
||
| 2 weeks |
| 2 weeks |
Revision as of 21:22, 9 March 2020
Background
- Infection of heart valves, either prosthetic or native
Organisms
- Bacteria
- Staphylococcus aureus (most common)
- Viridans group streptococci
- Coagulase-negative staphylococci
- Other streptococci
- Enterococci
- HACEK group
- Coxiella
- Brucella
- Fungi
Clinical Presentation
- Refer to Modified Duke criteria
- Specific organisms may be associated with specific risk factors
- Injection drug use: Viridans group streptococci and Pseudomonas aeruginosa
- Colon cancer: [Streptococcus bovis]] and Clostridium septicum
Management
- Varies by causative organism and prosthetic vs. native valve
Indication | Antibiotic | Dose | Duration | Notes |
---|---|---|---|---|
MSSA and other oxacillin-susceptible Staphylococcus | ||||
NVE | oxacillin | 2 g IV q4h | 6 weeks | can treat for 2 weeks in uncomplicated right-sided NVE |
NVE | cefazolin | 2 g IV q8h | 6 weeks | in patients with non-anaphylactoid penicillin allergy |
PVE | oxacillin | 2 g IV q4h | ≥6 weeks | use cefazolin or vancomycin if allergy |
+ rifampin | 300 mg IV/PO q8h | |||
+ gentamicin | 1 mg/kg IV/IM q8h | 2 weeks | ||
MRSA and other oxacillin-resistant Staphylococcus | ||||
NVE | vancomycin | 15 mg/kg IV q12h | 6 weeks | target trough 10-20 μg/mL |
NVE | daptomycin | ≥8 mg/kg/dose | 6 weeks | |
PVE | vancomycin | 15 mg/kg IV q12h | ≥6 weeks | target vancomycin trough of 10-20 μg/mL |
+ rifampin | 300 mg IV/PO q8h | |||
+ gentamicin | 1 mg/kg IV/IM q8h | 2 weeks | ||
Enterococcus susceptible to penicillin and gentamicin | ||||
NVE or PVE | ampicillin | 2 g IV q4h | 4-6 weeks | 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or if PVE |
+ gentamicin | 1 mg/kg IV q8h | |||
NVE or PVE | ampicillin | 2 g IV q4h | 6 weeks | alternative regimen if CrCl <50 |
+ ceftriaxone | 2 g IV q12h | |||
Enterococcus susceptible to penicillin and resistant to aminoglycosides | ||||
NVE or PVE | ampicillin | 2 g IV q4h | 6 weeks | |
+ ceftriaxone | 2 g IV q12h | |||
Enterococcus resistant to penicillin and susceptible to vancomycin and aminoglycosides | ||||
NVE or PVE | vancomycin | 15 mg/kg IV q12h | 6 weeks | |
+ gentamicin | 1 mg/kg IV/IM q8h | |||
Enterococcus resistant to penicillin, aminoglycosides, and vancomycin | ||||
NVE or PVE | linezolid | 600 mg IV/PO q12h | >6 weeks | |
NVE or PVE | daptomycin | 10-12 mg/kg IV q24h | >6 weeks | |
Viridans Streptococcus or Streptococcus gallolyticus highly susceptible to penicillin (MIC ≤0.12 μg/mL) | ||||
NVE | crystalline penicillin G | 3-4 MU IV q4h | 4 weeks | |
NVE | ceftriaxone | 2 g IV/IM q24h | 4 weeks | |
NVE | penicillin or ceftriaxone | as above | 2 weeks | |
+ gentamicin | 3 mg/kg IV/IM q24h | |||
NVE | vancomycin | 15 mg/kg IV q12h | 4 weeks | use if allergy, target 10-15 μg/mL |
PVE | crystalline penicillin G | 6 MU IV q4h | 6 weeks | |
± gentamicin | 3 mg/kg IV/IM q24h | 2 weeks | ||
PVE | ceftriaxone | 2 g IV/IM q24h | 6 weeks | |
± gentamicin | 3 mg/kg IV/IM q24h | 2 weeks | ||
PVE | vancomycin | 15 mg/kg IV q12h | 6 weeks | use if allergy |
Viridans Streptococcus or Streptococcus gallolyticus relatively resistant to penicillin (MIC >0.12 μg/mL) | ||||
NVE | crystalline penicillin G | 6 MU IV q4h | 4 weeks | |
+ gentamicin | 3 mg/kg IV/IM q24h | |||
NVE | vancomycin | 15 mg/kg IV q12h | 4 weeks | use if allergy, target 10-15 μ/mL |
PVE | crystalline penicillin G | 6 MU IV q4h | 6 weeks | |
+ gentamicin | 3 mg/kg IV/IM q24h | |||
PVE | ceftriaxone | 2 g IV/IM q24h | 6 weeks | |
+ gentamicin | 3 mg/kg IV/IM q24h | |||
PVE | vancomycin | 15 mg/kg IV q12h | 6 weeks | use if allergy |
Streptococcus pneumoniae | ||||
NVE | penicillin | 4 weeks | ||
NVE | cefazolin | 4 weeks | ||
NVE | ceftriaxone | 4 weeks | ||
PVE | penicillin | 6 weeks | ||
PVE | cefazolin | 6 weeks | ||
PVE | ceftriaxone | 6 weeks | ||
Streptococcus pyogenes | ||||
NVE | crystalline penicillin G | 4 weeks | ||
NVE | ceftriaxone | 4 weeks | ||
PVE | crystalline penicillin G | 6 weeks | ||
PVE | ceftriaxone | 6 weeks | ||
Group B, C, or G Streptococcus | ||||
NVE | crystalline penicillin G | 4 weeks | ||
± gentamicin | 2 weeks | |||
NVE | ceftriaxone | 4 weeks | ||
± gentamicin | 2 weeks | |||
PVE | crystalline penicillin G | 6 weeks | ||
± gentamicin | 2 weeks | |||
PVE | ceftriaxone | 6 weeks | ||
± gentamicin | 2 weeks | |||
HACEK bacterium | ||||
NVE | ceftriaxone | 2 g IV/IM q24h | 4 weeks | |
PVE | ceftriaxone | 2 g IV/IM q24h | 6 weeks | |
NVE or PVE | ciprofloxacin | 500 mg PO q12h | 6 weeks |
References
- ^ Kasper Iversen, Nikolaj Ihlemann, Sabine U. Gill, Trine Madsen, Hanne Elming, Kaare T. Jensen, Niels E. Bruun, Dan E. Høfsten, Kurt Fursted, Jens J. Christensen, Martin Schultz, Christine F. Klein, Emil L. Fosbøll, Flemming Rosenvinge, Henrik C. Schønheyder, Lars Køber, Christian Torp-Pedersen, Jannik Helweg-Larsen, Niels Tønder, Claus Moser, Henning Bundgaard. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. New England Journal of Medicine. 2019;380(5):415-424. doi:10.1056/nejmoa1808312.
- ^ John A Wildenthal, Andrew Atkinson, Sophia Lewis, Sena Sayood, Nathanial S Nolan, Nicolo L Cabrera, Jonas Marschall, Michael J Durkin, Laura R Marks. Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs. Clinical Infectious Diseases. 2022;76(3):487-496. doi:10.1093/cid/ciac714.
- ^ Sarah Freling, Noah Wald-Dickler, Josh Banerjee, Catherine P Canamar, Soodtida Tangpraphaphorn, Dara Bruce, Kusha Davar, Fernando Dominguez, Daniel Norwitz, Ganesh Krishnamurthi, Lilian Fung, Ashley Guanzon, Emi Minejima, Michael Spellberg, Catherine Spellberg, Rachel Baden, Paul Holtom, Brad Spellberg. Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study. Clinical Infectious Diseases. 2023;77(5):672-679. doi:10.1093/cid/ciad119.